Liriodendrin
Catalog No: CFN98964
Liriodendrin has anti-inflammatory, antinociceptive, hypoglycemic activities, it plays protective role in sepsis-induced acute lung injury, it regulates lung inflammation, the phosphorylation of the NF-kB (p65) and expression of vascular endothelial growth factor (VEGF). Liriodendrin has protective effects on dopamine-induced cytotoxicity via its anti-oxidative properties by reducing ROS level and anti-apoptotic effect via protection of mitochondrion membrane potential (ΔΨm). It may be a potent suppressor of CaCl(2)-induced arrhythmias, the prophylactic administration of liriodendrin is effective in prolonging latency of arrhythmia and reducing the occurrence of ventricular fibrillation from 75% to 25%. Liriodendrin has inhibitory activities on gastritis and gastric ulcer, it can inhibit colonization of Helicobacter pylori effectively, it could be utilized for the treatment and/or protection of gastritis and gastric ulcer.
Isofuranodiene
Catalog No: CFN98971
Isofuranodiene protects GalN/LPS-induced liver injury in SD rats, it may be a potential functional food ingredient for the prevention and treatment of liver diseases. Isofuranodiene has anticancer activity, by inhibiting the proliferation and inducing apoptosis in cancer cells; it
can induce apoptosis in colon cancer cells in a time and concentration-dependent manner suggesting a potential role as models for the development of chemopreventive agents. Isofuranodiene at concentrations of 25 and 12.5 lM alone, or in combination with 50 nM nerve growth factor (NGF) , shows a marked stimulation of neuritogenesis,which appears to be a promising neurotrophic and neuroprotective agent.
Aurantiamide
Catalog No: CFN98984
Aurantiamide acetate has anti-cancer, anti-inflammatory and antinociceptive activities, it may suppress the growth of malignant gliomas by blocking autophagic flux, it also inhibits cysteine proteinases, in particular, cathepsin L (3.4.22.15) and B (3.4.22.1) with IC50 of 12 microM and 49 microM, respectively . Aurantiamide acetate has an anti-neuroinflammatory effect on LPS stimulation through its inhibition of the NF-κB, JNK and p38 pathways.
